Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecirasib plus Sacituzumab Tirumotecan as second-line therapy in KRAS G12C-mutant NSCLC
ChiCTR2600127971Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glecirasib and sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoint: objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
glecirasibsacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600127971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127971.